^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AGI-101H

i
Other names: AGI-101H
Associations
Trials
Company:
National Cancer Institute
Drug class:
Vascular disrupting agent
Associations
Trials
almost4years
Functional T Cell Reactivity to Melanocyte Antigens Is Lost during the Progression of Malignant Melanoma, but Is Restored by Immunization. (PubMed, Cancers (Basel))
Third, we show that immunization with MA restored natural CD8+ T cell autoimmunity to MA in 85% of the MM patients. The role of natural T cell autoimmunity to tumor-associated MA is discussed based on discrete levels of T cell activation thresholds.
Journal
|
IFNG (Interferon, gamma)
|
AGI-101H
almost5years
Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6. (PubMed, Oncoimmunology)
In the present study, high levels of BCL6 transcripts negatively correlated with the expression of several exhaustion markers (CTLA4, KLRG1, PTGER2, IKZF2, TIGIT). Therefore, Bcl6 seems to promote a progenitor fate for cancer-experienced T cells from AGI-101H-vaccinated patients by repressing the exhaustion markers.
Journal
|
BCL6 (B-cell CLL/lymphoma 6) • IL2 (Interleukin 2)
|
AGI-101H